GlassScriptPhysician profile
Michael F Calabrese
NPI 1447318084
$1,946.47
in general payments reported to CMS, 2019-2025
25 companies · $168 in 2025
The $168 reported for 2025 was more than what 86% of Chiropractor providers received nationally (typical 2025 total: $40.91).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.21 · 2020: $274 · 2021: $430 · 2022: $340 · 2023: $425 · 2024: $210 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $635.70 | 2019-2024 | Synthroid |
| Takeda Pharmaceuticals U.S.A., INC. | $347.24 | 2020-2024 | Trintellix |
| Shield Therapeutics INC | $190.99 | 2023-2025 | Accrufer |
| Exact Sciences Corporation | $143.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $134.98 | 2023-2024 | Rexulti |
| Dynavax Technologies Corporation | $50.15 | 2020-2023 | Heplisav-B |
| Pfizer INC. | $38.95 | 2020-2024 | |
| Otsuka America Pharmaceutical, INC. | $38.41 | 2023-2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $35.68 | 2021 | |
| Medtronic, INC. | $35.03 | 2022 | |
| Redhill Biopharma INC. | $28.01 | 2021 | |
| Daiichi Sankyo INC. | $24.48 | 2021 | |
| Amarin Pharma, INC. | $23.39 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $23.15 | 2020 | |
| Genentech USA, INC. | $21.53 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $20.64 | 2022 | |
| Zyla Life Sciences, INC. | $20.09 | 2020 | |
| Assertio Therapeutics, INC. | $20.02 | 2020 | |
| Sanofi Pasteur INC. | $18.92 | 2023 | |
| Phadia US INC. | $17.95 | 2024 | Immunocap |
| Arbor Pharmaceuticals, INC. | $17.15 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.11 | 2024 | Quviviq |
| Adlon Therapeutics L.P. | $15.19 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.44 | 2020 | |
| Dermira, INC. | $14.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Calabrese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.